Literature DB >> 17085048

Nitrogen-containing flavonoids as CDK1/Cyclin B inhibitors: design, synthesis, and biological evaluation.

Tao Liu1, Zhongmiao Xu, Qiaojun He, Yanhong Chen, Bo Yang, Yongzhou Hu.   

Abstract

A novel series of nitrogen-containing flavonoids 5a-l, 6a,b, and 7a,b were designed and synthesized as cyclin-dependent kinases (CDKs) inhibitors. The representative compounds 5a, 5b, 5e, and 5g showed potent CDK1/Cyclin B inhibitory activities. All compounds displayed a significant growth inhibitory action in vitro against Bel-7402, PC-3, ECA-109, A-549, HL-60, and MCF-7 cancer cell lines. Flow cytometry analysis showed that 5b induced apoptosis in PC-3 cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17085048     DOI: 10.1016/j.bmcl.2006.07.088

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  4 in total

1.  Synthesis and tautomerization of hydroxylated isoflavones bearing heterocyclic hemi-aminals.

Authors:  Mykhaylo S Frasinyuk; Svitlana P Bondarenko; Volodymyr P Khilya; Chunming Liu; David S Watt; Vitaliy M Sviripa
Journal:  Org Biomol Chem       Date:  2014-11-21       Impact factor: 3.876

2.  Efficient Synthesis of Aurone Mannich Bases and Evaluation of their Antineoplastic Activity in PC-3 Prostate Cancer Cells.

Authors:  Antonina V Popova; Mykhaylo S Frasinyuk; Svitlana P Bondarenko; Wen Zhang; Yanqi Xie; Zachary M Martin; Xianfeng Cai; Michael V Fiandalo; James L Mohler; Chunming Liu; David S Watt; Vitaliy M Sviripa
Journal:  Chem Zvesti       Date:  2018-04-28       Impact factor: 2.146

3.  Synthesis and antiproliferative activity of pterostilbene and 3′-methoxy pterostilbene Mannich base derivatives against Hela cells.

Authors:  Chongyang Liu; Linpei Dong; Shengchun Wang; Qiuan Wang
Journal:  Mol Divers       Date:  2015-07-11       Impact factor: 2.943

4.  Flavonoids as CDK1 Inhibitors: Insights in Their Binding Orientations and Structure-Activity Relationship.

Authors:  Carlos Navarro-Retamal; Julio Caballero
Journal:  PLoS One       Date:  2016-08-12       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.